Sean Guerre of Innovate Energy joins the Houston Innovators Podcast to share how energy startups are especially challenged in the current climate. Photo courtesy of Innovate Energy

The oil and gas industry has been hit with a double whammy of challenges with COVID-19 and its imminent recession, but the global industry was already facing an oversupply of oil — and now an even smaller demand.

One of this confluence of obstacles' victims is going to be early-stage energy tech startups, Sean Guerre, managing director of Innovate Energy, says on this week's episode of the Houston Innovators Podcast.

"When you think about what's happening in the oil downturn, unfortunately it's just a slice in huge uncertainty sandwich that we're all having to go through right now," Guerre says.

Not only is the pandemic unprecedented, but the cyclical energy industry hasn't faced a situation with so much discrepancy between supply and demand since the 1930s, which is a bit too far back to really take in any lessons learned.

Energy tech startups that are pre-funding and pre-pilots are going to struggle to get a foot in the door at bigger companies and aren't going to find much funding — both venture capital and corporate venture are down, Guerre says. He recommends really focusing on messaging moving forward — startups need to pitch cost-saving and efficient solutions.

"You've got to make sure your message fits the market," Guerre says. "What was working four weeks ago is probably not what you're going forth with now."

Innovate Energy, which produces online content for the advancement of energy tech and innovation, has seen a rise in interest in digital and unmanned solutions like robotics and industrial virtual reality.

"We're seeing a huge interest in autonomous, unmanned solutions," Guerre says. "Anything in that remote, autonomous area that allows people to continue to do inspections, mapping, surveying, and all kinds of work that don't involve more people being involved in the process — we're seeing a real acceleration there."

Startups are also challenged with a lack of events and networking opportunities with the COVID-19 mandates to stay at home and social distance. Guerre, who founded Stone Fort Group to put on virtual and in-person programming, says it's a new burden on event holders to use technology to optimize their events for the happenstance and socialization that happens at in-person events.

"How do we actually help people connect who wouldn't normally would have connected if they hadn't been sitting next to each other in a general session or waiting in line at the coffee line," he says on the show.

Guerre shares his thoughts on the state of energy moving forward, and how key these virtual events are on the podcast. Listen to the full episode below — or wherever you get your podcasts — and subscribe for weekly episodes.



Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”